Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal clinical study of Lecigon for advanced Parkinson's disease

X
Trial Profile

A pivotal clinical study of Lecigon for advanced Parkinson's disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 07 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levodopa/carbidopa/entacapone (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Intrance Medical Systems
  • Most Recent Events

    • 04 Jan 2022 According to an Intrance Medical Systems media release, company has completed the final round of a Series A financing, totaling USD $17 million. Proceeds from the financing will be used to initiate this study.
    • 21 Aug 2021 New trial record
    • 17 Aug 2021 According to an Intrance Medical Systems media release, the company has filed an Investigational New Drug (IND) application for Lecigon with the U.S. Food and Drug Administration (FDA) to advance its U.S. clinical development program.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top